Conduit Pharmaceuticals (CDT) News Today $0.08 +0.02 (+26.62%) (As of 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Conduit Pharmaceuticals faces Nasdaq delisting over price, votes for reverse splitDecember 23, 2024 | investing.comConduit Pharmaceuticals Faces Nasdaq Delisting, Plans Stock SplitDecember 21, 2024 | markets.businessinsider.comConduit and Sarborg link to optimise AI drug developmentDecember 14, 2024 | msn.comConduit Pharmaceuticals to enter agreement with SARBORDecember 13, 2024 | markets.businessinsider.comConduit Collaborates With Sarborg To Facilitate Drug Development, Stock Up In Pre-MarketDecember 12, 2024 | markets.businessinsider.comConduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and CyberneticsDecember 12, 2024 | globenewswire.comConduit Pharmaceuticals receives further patent approval for AZD1656November 21, 2024 | markets.businessinsider.comWhat's Going On With Conduit Pharmaceuticals Shares Today?November 21, 2024 | benzinga.comConduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune DisordersNovember 21, 2024 | globenewswire.comConduit Pharmaceuticals Announces Leadership Changes and Bylaws UpdateNovember 20, 2024 | markets.businessinsider.comConduit Pharmaceuticals Announces Appointment of Simon Fry to Board of DirectorsNovember 19, 2024 | globenewswire.comConduit Pharmaceuticals announces new addition to autoimmune pipelineNovember 5, 2024 | markets.businessinsider.comConduit Pharmaceuticals Announces New Addition to its Autoimmune PipelineNovember 4, 2024 | globenewswire.comConduit Pharmaceuticals Secures Funding and Modifies Debt AgreementsNovember 1, 2024 | markets.businessinsider.comConduit Pharmaceuticals Announces Debt Restructuring and Additional NotesNovember 1, 2024 | globenewswire.comLtd Nirland Sells 939,009 Shares of Conduit Pharmaceuticals Inc. (NASDAQ:CDT) StockOctober 8, 2024 | insidertrades.comConduit Pharmaceuticals executives sell shares worth over $297kOctober 4, 2024 | investing.comConduit Pharmaceuticals Inc. (NASDAQ:CDT) Major Shareholder Sells $33,317.70 in StockOctober 3, 2024 | insidertrades.comAndrew Regan Sells 35,923 Shares of Conduit Pharmaceuticals Inc. (NASDAQ:CDT) StockSeptember 20, 2024 | insidertrades.comConduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 28, 2024 | finance.yahoo.comWhy Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?August 14, 2024 | investorplace.comConduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune DisordersAugust 12, 2024 | globenewswire.comConduit Pharmaceuticals (NASDAQ:CDT) Stock, Short Interest ReportAugust 9, 2024 | benzinga.com4 Stocks Moving Sharply Before the Market Opens: CDT, XPON, WENA, ADDAugust 8, 2024 | msn.comConduit Pharmaceuticals Shares Soar In Pre-market, Why?August 8, 2024 | markets.businessinsider.comEXCLUSIVE: Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple AssetsAugust 8, 2024 | msn.com4 Stocks Moving Sharply Before the Market OpensAugust 8, 2024 | 247wallst.comWhy Is Conduit Pharmaceuticals (CDT) Stock Up 123% Today?August 8, 2024 | investorplace.comEXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple AssetsAugust 8, 2024 | finance.yahoo.comConduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class TreatmentsAugust 8, 2024 | globenewswire.comRobert Courtney diluted thousands of prescriptions. How was he finally caught?July 23, 2024 | msn.comWhy Is Conduit Pharmaceuticals (CDT) Stock Up 73% Today?July 16, 2024 | investorplace.comConduit Pharmaceuticals Inc. (NASDAQ:CDT) Sees Large Increase in Short InterestConduit Pharmaceuticals Inc. (NASDAQ:CDT - Get Free Report) saw a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 56,800 shares, an increase of 72.6% from the May 31st total of 32,900 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average daily trading volume, of 44,100 shares, the short-interest ratio is currently 1.3 days.June 28, 2024 | marketbeat.comAstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024May 22, 2024 | businesswire.comCDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q1 2024May 15, 2024 | investorplace.comConduit Pharmaceuticals Inc. (NASDAQ:CDT) Sees Significant Decrease in Short InterestConduit Pharmaceuticals Inc. (NASDAQ:CDT - Get Free Report) was the recipient of a significant decrease in short interest in March. As of March 31st, there was short interest totalling 55,100 shares, a decrease of 29.2% from the March 15th total of 77,800 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average daily volume of 39,800 shares, the days-to-cover ratio is currently 1.4 days.April 12, 2024 | marketbeat.comConduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Up 12.8% in MarchConduit Pharmaceuticals Inc. (NASDAQ:CDT - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 77,800 shares, a growth of 12.8% from the February 29th total of 69,000 shares. Currently, 0.8% of the shares of the company are sold short. Based on an average daily volume of 43,400 shares, the days-to-cover ratio is currently 1.8 days.April 1, 2024 | marketbeat.comConduit Pharmaceuticals Adds Key Leadership PositionsMarch 19, 2024 | finance.yahoo.comConduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific OfficerMarch 19, 2024 | globenewswire.comShort Interest in Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Decreases By 39.1%Conduit Pharmaceuticals Inc. (NASDAQ:CDT - Get Free Report) saw a large drop in short interest during the month of February. As of February 29th, there was short interest totalling 69,000 shares, a drop of 39.1% from the February 14th total of 113,300 shares. Based on an average daily trading volume, of 98,800 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.7% of the shares of the company are sold short.March 14, 2024 | marketbeat.comConduit Pharmaceuticals Opens New Laboratory in UKMarch 11, 2024 | finance.yahoo.comConduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences HubMarch 11, 2024 | finance.yahoo.comConduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe's Leading Life Sciences HubMarch 11, 2024 | globenewswire.comShort Interest in Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Declines By 13.2%Conduit Pharmaceuticals Inc. (NASDAQ:CDT - Get Free Report) was the target of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 113,300 shares, a decrease of 13.2% from the January 31st total of 130,500 shares. Approximately 1.1% of the company's shares are short sold. Based on an average trading volume of 148,400 shares, the days-to-cover ratio is presently 0.8 days.March 3, 2024 | marketbeat.comConduit Pharmaceuticals: Stellar Management Team, New Business ModelFebruary 28, 2024 | seekingalpha.comConduit Pharmaceuticals (NASDAQ:CDT) Trading 6.8% Higher Conduit Pharmaceuticals (NASDAQ:CDT) Trading Up 6.8%February 23, 2024 | marketbeat.comConduit Pharmaceuticals Inc. (CDT)February 15, 2024 | sg.finance.yahoo.comConduit Pharmaceuticals Inc. (CDTTW)February 13, 2024 | uk.finance.yahoo.comConduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 31, 2024 | finance.yahoo.comTrading was temporarily halted for "CDT" at 11:12 AM with a stated reason of "LULD pause."December 13, 2023 | marketbeat.com Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address Missed Nvidia? Buy Elon Musk’s “Silent Partner” (Ad)In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner. So please click here to see the details because a lot of people could get rich. CDT Media Mentions By Week CDT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDT News Sentiment▼0.220.59▲Average Medical News Sentiment CDT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDT Articles This Week▼41▲CDT Articles Average Week Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NKGen Biotech News iBio News Equillium News Mannatech News Pulmatrix News NanoViricides News Citius Pharmaceuticals News GeoVax Labs News MiNK Therapeutics News Athira Pharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDT) was last updated on 12/30/2024 by MarketBeat.com Staff From Our PartnersKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
